SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARRIS - Another partner
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe C. who wrote (322)12/15/1997 2:14:00 PM
From: Steve Lokness  Read Replies (1) of 353
 
Hi Joe;
You ask an important question that seems to have been lost with all the discussion on the merger. While there seems to be little question that management at ARRS is top notch, there is a difference of opinion as to if the merger is good for shareholder value. I believe that with all that SQNA brings to the merger that the "path" to new drug discovery is enhanced by the combined co. You also bring up an interesting point when you say that ARRS is "financially conservative". That is one of the reasons I believe that the merger will be good in the long run for ARRS holders - because SQNA brings such a strong cash position as well as future expected cash to the new company. Others have obviously disagreed. Whatever you think of the merger it is hard to believe that the "path" to new drug discovery will not be enhanced by the new co.

Good Luck!
Steve
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News